Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: A retrospective review within the era of temozolomide

Nicole A Shonka, Brett Theeler, Daniel Cahill, Alfred Yung, Lynette M Smith, Xiudong Lei, Mark R. Gilbert

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Treatment for anaplastic astrocytoma (AA) is controversial. To assess three primary treatment approaches, patients from a single institution were retrospectively evaluated. To represent modern treatment selection, patients diagnosed with AA from December 2003 to December 2009 were selected. Those with insufficient data, incomplete pathology, and transformation or reclassification to glioblastoma in fewer than 6 months were excluded. A total of 163 patients were included in the final analyses. Median follow-up time was 4.2 years (range 0.5-7.8 years). Median age and Karnofsky performance status at diagnosis were 39.2 years and 90, respectively. 23.6 % of patients underwent biopsy, and 72.2 % underwent resection. Approximately 31 % received concurrent chemoradiation (CRT), 26.1 % had radiation therapy alone (RT), 38.2 % had radiation therapy followed by chemotherapy (RT-C), and 3 % were treated only with chemotherapy. Temozolomide was used almost exclusively during CRT (94.2 %) and adjuvantly. A median of 9.5 cycles of adjuvant chemotherapy was given. The combination of radiation and chemotherapy, either concurrent or sequential trended toward a higher rate of radiation necrosis. Median progression free survival (PFS) favored RT (not reached) over CRT (1.5 years) and RT-C (3.6 years) adjusted for pairwise comparison (p = 0.033, p = 0.050). Median overall survival (OS) was 5.7 years, and did not differ significantly by treatment group. OS for patients with AA did not vary by initial treatment selection. Although the longer PFS in those receiving RT versus CRT may be confounded by pseudoprogression, the equivalent OS among groups supports RT.

Original languageEnglish (US)
Pages (from-to)305-311
Number of pages7
JournalJournal of Neuro-Oncology
Volume113
Issue number2
DOIs
StatePublished - Jun 1 2013

Fingerprint

temozolomide
Astrocytoma
Radiotherapy
Drug Therapy
Disease-Free Survival
Survival
Radiation
Therapeutics
Karnofsky Performance Status
Adjuvant Chemotherapy
Glioblastoma
Combination Drug Therapy
Patient Selection
Necrosis

Keywords

  • Anaplastic astrocytoma
  • Chemotherapy
  • Radiation therapy
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy : A retrospective review within the era of temozolomide. / Shonka, Nicole A; Theeler, Brett; Cahill, Daniel; Yung, Alfred; Smith, Lynette M; Lei, Xiudong; Gilbert, Mark R.

In: Journal of Neuro-Oncology, Vol. 113, No. 2, 01.06.2013, p. 305-311.

Research output: Contribution to journalArticle

@article{a952e4875fa34983804fef0da05bed28,
title = "Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: A retrospective review within the era of temozolomide",
abstract = "Treatment for anaplastic astrocytoma (AA) is controversial. To assess three primary treatment approaches, patients from a single institution were retrospectively evaluated. To represent modern treatment selection, patients diagnosed with AA from December 2003 to December 2009 were selected. Those with insufficient data, incomplete pathology, and transformation or reclassification to glioblastoma in fewer than 6 months were excluded. A total of 163 patients were included in the final analyses. Median follow-up time was 4.2 years (range 0.5-7.8 years). Median age and Karnofsky performance status at diagnosis were 39.2 years and 90, respectively. 23.6 {\%} of patients underwent biopsy, and 72.2 {\%} underwent resection. Approximately 31 {\%} received concurrent chemoradiation (CRT), 26.1 {\%} had radiation therapy alone (RT), 38.2 {\%} had radiation therapy followed by chemotherapy (RT-C), and 3 {\%} were treated only with chemotherapy. Temozolomide was used almost exclusively during CRT (94.2 {\%}) and adjuvantly. A median of 9.5 cycles of adjuvant chemotherapy was given. The combination of radiation and chemotherapy, either concurrent or sequential trended toward a higher rate of radiation necrosis. Median progression free survival (PFS) favored RT (not reached) over CRT (1.5 years) and RT-C (3.6 years) adjusted for pairwise comparison (p = 0.033, p = 0.050). Median overall survival (OS) was 5.7 years, and did not differ significantly by treatment group. OS for patients with AA did not vary by initial treatment selection. Although the longer PFS in those receiving RT versus CRT may be confounded by pseudoprogression, the equivalent OS among groups supports RT.",
keywords = "Anaplastic astrocytoma, Chemotherapy, Radiation therapy, Treatment",
author = "Shonka, {Nicole A} and Brett Theeler and Daniel Cahill and Alfred Yung and Smith, {Lynette M} and Xiudong Lei and Gilbert, {Mark R.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1007/s11060-013-1116-4",
language = "English (US)",
volume = "113",
pages = "305--311",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy

T2 - A retrospective review within the era of temozolomide

AU - Shonka, Nicole A

AU - Theeler, Brett

AU - Cahill, Daniel

AU - Yung, Alfred

AU - Smith, Lynette M

AU - Lei, Xiudong

AU - Gilbert, Mark R.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Treatment for anaplastic astrocytoma (AA) is controversial. To assess three primary treatment approaches, patients from a single institution were retrospectively evaluated. To represent modern treatment selection, patients diagnosed with AA from December 2003 to December 2009 were selected. Those with insufficient data, incomplete pathology, and transformation or reclassification to glioblastoma in fewer than 6 months were excluded. A total of 163 patients were included in the final analyses. Median follow-up time was 4.2 years (range 0.5-7.8 years). Median age and Karnofsky performance status at diagnosis were 39.2 years and 90, respectively. 23.6 % of patients underwent biopsy, and 72.2 % underwent resection. Approximately 31 % received concurrent chemoradiation (CRT), 26.1 % had radiation therapy alone (RT), 38.2 % had radiation therapy followed by chemotherapy (RT-C), and 3 % were treated only with chemotherapy. Temozolomide was used almost exclusively during CRT (94.2 %) and adjuvantly. A median of 9.5 cycles of adjuvant chemotherapy was given. The combination of radiation and chemotherapy, either concurrent or sequential trended toward a higher rate of radiation necrosis. Median progression free survival (PFS) favored RT (not reached) over CRT (1.5 years) and RT-C (3.6 years) adjusted for pairwise comparison (p = 0.033, p = 0.050). Median overall survival (OS) was 5.7 years, and did not differ significantly by treatment group. OS for patients with AA did not vary by initial treatment selection. Although the longer PFS in those receiving RT versus CRT may be confounded by pseudoprogression, the equivalent OS among groups supports RT.

AB - Treatment for anaplastic astrocytoma (AA) is controversial. To assess three primary treatment approaches, patients from a single institution were retrospectively evaluated. To represent modern treatment selection, patients diagnosed with AA from December 2003 to December 2009 were selected. Those with insufficient data, incomplete pathology, and transformation or reclassification to glioblastoma in fewer than 6 months were excluded. A total of 163 patients were included in the final analyses. Median follow-up time was 4.2 years (range 0.5-7.8 years). Median age and Karnofsky performance status at diagnosis were 39.2 years and 90, respectively. 23.6 % of patients underwent biopsy, and 72.2 % underwent resection. Approximately 31 % received concurrent chemoradiation (CRT), 26.1 % had radiation therapy alone (RT), 38.2 % had radiation therapy followed by chemotherapy (RT-C), and 3 % were treated only with chemotherapy. Temozolomide was used almost exclusively during CRT (94.2 %) and adjuvantly. A median of 9.5 cycles of adjuvant chemotherapy was given. The combination of radiation and chemotherapy, either concurrent or sequential trended toward a higher rate of radiation necrosis. Median progression free survival (PFS) favored RT (not reached) over CRT (1.5 years) and RT-C (3.6 years) adjusted for pairwise comparison (p = 0.033, p = 0.050). Median overall survival (OS) was 5.7 years, and did not differ significantly by treatment group. OS for patients with AA did not vary by initial treatment selection. Although the longer PFS in those receiving RT versus CRT may be confounded by pseudoprogression, the equivalent OS among groups supports RT.

KW - Anaplastic astrocytoma

KW - Chemotherapy

KW - Radiation therapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84879092884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879092884&partnerID=8YFLogxK

U2 - 10.1007/s11060-013-1116-4

DO - 10.1007/s11060-013-1116-4

M3 - Article

C2 - 23526410

AN - SCOPUS:84879092884

VL - 113

SP - 305

EP - 311

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -